Abstract
Sigma receptors are classified into sigma1 and sigma2 subtypes. These subtypes display a different tissue distribution and a distinct physiological and pharmacological profile in the central and peripheral nervous system. The characterization of these subtypes and the discovery of new specific sigma receptor ligands demonstrated that sigma receptors are novel targets for the therapeutic treatment of neuropsychiatric diseases (schizophrenia, depression, and cognition), brain ischemia, and cocaine addiction. Furthermore, imaging of sigma1 receptors in the human brain using specific PET radioligands has started. In addition, the two sigma receptor subtypes are also expressed on tumor cells, where they could be of prognostic relevance. The ability of sigma2 receptor agonists to inhibit tumor cell proliferation through mechanisms that might involve apoptosis, intracellular Ca2+, and sphingolipids has promoted the development of sigma2 receptor agonists as novel therapeutic drugs for treating cancer. Consequently, sigma2 receptor ligands have been demonstrated to be potentially useful tumor imaging ligands. In this article, we focus on the sigma receptor ligands as therapeutic agents and as radiopharmaceuticals.
Keywords: CNS, NMDA receptor, antidepressants, 4-phenyl-1-(4-phenylbutyl)-piperidine (PPBP), ischemia, Cocaine addiction
Current Pharmaceutical Design
Title: Sigma Receptor Ligands: Possible Application as Therapeutic Drugs and as Radiopharmaceuticals
Volume: 12 Issue: 30
Author(s): Kiichi Ishiwata and Kenji Hashimoto
Affiliation:
Keywords: CNS, NMDA receptor, antidepressants, 4-phenyl-1-(4-phenylbutyl)-piperidine (PPBP), ischemia, Cocaine addiction
Abstract: Sigma receptors are classified into sigma1 and sigma2 subtypes. These subtypes display a different tissue distribution and a distinct physiological and pharmacological profile in the central and peripheral nervous system. The characterization of these subtypes and the discovery of new specific sigma receptor ligands demonstrated that sigma receptors are novel targets for the therapeutic treatment of neuropsychiatric diseases (schizophrenia, depression, and cognition), brain ischemia, and cocaine addiction. Furthermore, imaging of sigma1 receptors in the human brain using specific PET radioligands has started. In addition, the two sigma receptor subtypes are also expressed on tumor cells, where they could be of prognostic relevance. The ability of sigma2 receptor agonists to inhibit tumor cell proliferation through mechanisms that might involve apoptosis, intracellular Ca2+, and sphingolipids has promoted the development of sigma2 receptor agonists as novel therapeutic drugs for treating cancer. Consequently, sigma2 receptor ligands have been demonstrated to be potentially useful tumor imaging ligands. In this article, we focus on the sigma receptor ligands as therapeutic agents and as radiopharmaceuticals.
Export Options
About this article
Cite this article as:
Ishiwata Kiichi and Hashimoto Kenji, Sigma Receptor Ligands: Possible Application as Therapeutic Drugs and as Radiopharmaceuticals, Current Pharmaceutical Design 2006; 12 (30) . https://dx.doi.org/10.2174/138161206778559614
DOI https://dx.doi.org/10.2174/138161206778559614 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Cellular and Molecular Mechanisms of Dementia: Decoding the Causal link of Diabetes Mellitus in Alzheimer’s Disease
CNS & Neurological Disorders - Drug Targets Epigenetic Regulation of Cytochrome P450 Enzymes and Clinical Implication
Current Drug Metabolism Volatilome Metabolomics and Databases, Recent Advances and Needs
Current Metabolomics Structure-Affinity-Relationship Study of Bicyclic σ Receptor Ligands
Central Nervous System Agents in Medicinal Chemistry Rationale and First Results of Developing At-Risk (Prodromal) Criteria for Bipolar Disorder
Current Pharmaceutical Design A Role for Calcineurin in Alzheimers Disease
Current Neuropharmacology Patent Annotations
Recent Patents on Anti-Infective Drug Discovery Mechanisms of Action of Antiepileptic Drugs
Current Topics in Medicinal Chemistry PTML Modeling for Alzheimer’s Disease: Design and Prediction of Virtual Multi-Target Inhibitors of GSK3B, HDAC1, and HDAC6
Current Topics in Medicinal Chemistry Functional Selectivity in Cannabinoid Signaling
Current Molecular Pharmacology Development, Validation and Application of an LC-MS/MS Bioanalytical Method for the Quantification of GF449, A Novel 5-HT<sub>1A</sub> Agonist, in Rat Plasma and Brain
Medicinal Chemistry Levosimendan: A Novel Agent in Heart Failure
Recent Patents on Cardiovascular Drug Discovery Demographic, Clinical and Laboratory Profiles of HIV Infected Patients Admitted into Imam Khomeini Hospital of Tehran, Iran
Infectious Disorders - Drug Targets Use of Speech Analyses within a Mobile Application for the Assessment of Cognitive Impairment in Elderly People
Current Alzheimer Research Mechanisms of Adeno-Associated Virus Genome Encapsidation
Current Gene Therapy Epinephrine and its Role in the Development of Obesity and Hypertension
Current Hypertension Reviews Activation of Melanocortin-4 Receptor by a Synthetic Agonist Inhibits Ethanolinduced Neuroinflammation in Rats
Current Pharmaceutical Design Involvement of Cytochromes P450 2D6, 2B6 and 2C19 in the Metabolism of (-)-Deprenyl and N-Methyl,N-propargylphenylethylamine
Drug Metabolism Letters Synthesis and Biological Evaluation of Novel N-[(7-pyridin-4-yl-2, 3- dihydro-benzofuran-2-yl) Methyl]-(4-methyl-1, 2, 3-thiadiazole-5-yl) Formamide as a Potent Immunosuppressant Agent
Letters in Drug Design & Discovery HPA Axis Function During the Perinatal Period in Patients with Affective Disorders
Current Psychiatry Reviews